A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response
Clinical trial NCT00758043 · COMPLETED
Trial details
- NCT number
- NCT00758043
- Sponsor
- Vertex Pharmaceuticals Incorporated
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2008-10-01
- Primary completion
- 2010-06-01
- Enrollment
- 540
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.